Effect of CYP2C19 Genotype on Ischemic Outcomes During Oral P2Y₁₂ Inhibitor Therapy: A Meta-Analysis.

ABSTRACT:

Objectives

The aim of this study was to examine the effect of CYP2C19 genotype on clinical outcomes in patients with coronary artery disease (CAD) who predominantly underwent percutaneous coronary intervention (PCI), comparing those treated with ticagrelor or prasugrel versus clopidogrel.

Background

The effect of CYP2C19 genotype on treatment outcomes with ticagrelor or prasugrel compared with clopidogrel is unclear.

Methods

Databases through February 19, 2020, were searched for studies reporting the effect of CYP2C19 genotype on ischemic outcomes during ticagrelor or prasugrel versus clopidogrel treatment. Study eligibility required outcomes reported for CYP2C19 genotype status and clopidogrel and alternative P2Y₁₂ inhibitors in patients with CAD with at l

SUBMITTER: Pereira NL 

PROVIDER: S-EPMC9853943 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature